Skip to Content
Skip to Navigation
Skip to Utility Navigation
Skip to Search

From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

Search for Sarcoma in Oncology and Hematology

Physician-authored summaries on the latest research on sarcoma, editorials on sarcoma, and perspectives on sarcoma - drawn from the top medical journals.

Sort by:

Relevance
Date

Items 1 to 20 of 36 results

You searched for: sarcoma in Oncology and Hematology

Longer Imatinib Therapy Effective for Gastrointestinal Stromal Tumors
- April 24, 2012
- David H. Ilson, MD, PhD
- Oncology and Hematology
Extending postoperative adjuvant treatment from 1 to 3 years improved recurrence-free and overall survival.
- Reviewing:
- Joensuu H et al., JAMA 2012 Mar 28; 307:1265. Blanke CD., JAMA 2012 Mar 28; 307:1312.
- Related Searches: adjuvant chemotherapy, gastrointestinal stromal tumor, imatinib mesylate
Early-Stage Hodgkin Lymphoma: New Lessons from an Old Study
- January 31, 2012
- Michael E. Williams, MD
- Oncology and Hematology
Overall survival was improved for patients treated with ABVD chemotherapy versus subtotal nodal irradiation.
- Reviewing:
- Meyer RM et al., N Engl J Med 2011 Dec 11;: Straus DJ., N Engl J Med 2011 Dec 11;:
- Related Searches: bleomycin/dacarbazine/doxorubicin/vinblastine protocol, hodgkin's disease, total nodal irradiation
Comparing Chemotherapies for Advanced Hodgkin Lymphoma
- August 2, 2011
- Michael E. Williams, MD
- Oncology and Hematology
Seven-year survival rates were similar with ABVD and BEACOPP.
- Reviewing:
- Viviani S et al., N Engl J Med 2011 Jul 21; 365:203.
- Related Searches: beacopp protocol, bleomycin/dacarbazine/doxorubicin/vinblastine protocol, chemotherapy, hodgkin's disease
ASCO 2011 Report: Gastrointestinal Cancer
- July 19, 2011
- David H. Ilson, MD, PhD
- Oncology and Hematology
Key trials focused on new therapies for colorectal, anal, gastric, and hepatocellular cancers.
- Related Searches: adjuvant chemotherapy, anal carcinoma, capecitabine, cisplatin, classic, colorectal cancer, colorectal cancer metastatic, crystal, docetaxel, epirubicin, fluorouracil, fluorouracil/leucovorin calcium/oxaliplatin, folinic acid-fluorouracil-irinotecan regimen, gastric cancer, gastrointestinal stromal tumor, imatinib mesylate, irinotecan, leucovorin, malignant neoplasm of stomach stage iv, mitomycin, opus, oxaliplatin, panitumumab, preoperative chemotherapy, prime, radiochemotherapy, rectal carcinoma, sorafenib, sunitinib, supportive care, watchful waiting
ASCO 2011 Report: Malignant Hematology
- July 5, 2011
- Michael E. Williams, MD
- Oncology and Hematology
The role of autologous stem-cell transplantation (ASCT) as consolidation treatment for higher-risk, aggressive B- and T-cell non-Hodgkin lymphomas (NHLs) remains controversial. In the phase III, . . .
- Related Searches: brentuximab vedotin, chronic lymphocytic leukemia, comfort-i, dasatinib, hematopoietic stem cell transplantation, hodgkin's disease, imatinib mesylate, incb018424, jak2 gene, leukemia, myelocytic, chronic, myelofibrosis, nilotinib, non-hodgkin's lymphoma, aggressive, pci 32765, rituximab, southwest oncology group
A Genetic Marker for Hairy Cell Leukemia
- June 14, 2011
- Michael E. Williams, MD
- Oncology and Hematology
HCL uniformly harbors a BRAF mutation that is not present in other B-cell malignancies.
- Reviewing:
- Tiacci E et al., N Engl J Med 2011 Jun 16; 364:2305.
- Related Searches: braf gene, genetic markers, hairy-cell leukemia, mutation
Molecular Markers and Stage II Colorectal Cancer
- May 17, 2011
- David H. Ilson, MD, PhD
- Oncology and Hematology
Defective DNA mismatch repair and KRAS mutation were prognostic, but not predictive, markers.
- Reviewing:
- Hutchins G et al., J Clin Oncol 2011 Apr 1; 29:1261.
- Related Searches: adjuvant chemotherapy, biological markers, braf gene, cancer surgery, colorectal cancer, fluorouracil, k-ras oncogene, leucovorin, mismatch repair, mutation, QUASAR
Morbidity and Mortality in Hodgkin Lymphoma Survivors
- March 22, 2011
- Michael G. Douvas, MD
- Oncology and Hematology
The growing population of HL survivors is at risk for long-term complications of therapy.
- Reviewing:
- Castellino SM et al., Blood 2011 Feb 10; 117:1806.
- Related Searches: cancer survivorship, CCSS, childhood cancer, hodgkin's disease, mortality
Report from the 52nd American Society of Hematology Annual Meeting Free
- January 18, 2011
- Michael E. Williams, MD
- Oncology and Hematology
The latest reports on treatments for a variety of lymphomas
- Related Searches: bleomycin/dacarbazine/doxorubicin/vinblastine protocol, brentuximab vedotin, cancer remission, cytarabine, follicular lymphoma, hodgkin's disease, ki-1+ anaplastic large cell lymphoma, lymphoma, mantle-cell, neoadjuvant therapy, rituximab, stanford v protocol, watchful waiting
Combination Therapy for Early Unfavorable Hodgkin Lymphoma
- November 30, 2010
- Michael E. Williams, MD
- Oncology and Hematology
Four cycles of chemotherapy plus involved-field radiotherapy were highly effective for stage I–II Hodgkin lymphoma with unfavorable clinical features.
- Reviewing:
- Eich HT et al., J Clin Oncol 2010 Sep 20; 28:4199.
- Related Searches: beacopp protocol, bleomycin/dacarbazine/doxorubicin/vinblastine protocol, chemotherapy, combined modality therapy, hodgkin's disease, radiation therapy
Targeted Therapy for Patients with Relapsed Hodgkin Lymphoma
- November 3, 2010
- Michael E. Williams, MD
- Oncology and Hematology
An antineoplastic agent conjugated to an anti-CD30 monoclonal antibody provided high response rates.
- Reviewing:
- Younes A et al., N Engl J Med 2010 Nov 4; 363:1812.
- Related Searches: angioimmunoblastic lymphadenopathy, antigens, cd30, brentuximab vedotin, hodgkin's disease, ki-1+ anaplastic large cell lymphoma, monoclonal antibodies
Is It Safe to Discontinue Imatinib for Advanced Gastrointestinal Stromal Tumors?
- November 2, 2010
- David H. Ilson, MD, PhD
- Oncology and Hematology
Interrupting treatment after 3 years led to relatively rapid disease progression.
- Reviewing:
- Le Cesne A et al., Lancet Oncol 2010 Oct; 11:942. Heinrich MC., Lancet Oncol 2010 Oct; 11:910.
- Related Searches: drug holiday, gastrointestinal stromal tumor, imatinib mesylate
Reduced-Intensity Therapy for Early-Stage Hodgkin Lymphoma Free
- August 11, 2010
- Michael E. Williams, MD
- Oncology and Hematology
Reduced-cycle chemotherapy plus lower-dose radiotherapy was highly effective in patients with stage I or II disease and favorable prognoses.
- Reviewing:
- Engert A et al., N Engl J Med 2010 Aug 12; 363:640.
- Related Searches: bleomycin/dacarbazine/doxorubicin/vinblastine protocol, hodgkin's disease, radiation therapy
Incidence of Thrombosis in Lymphoma Patients
- August 3, 2010
- David Green, MD, PhD
- Oncology and Hematology
Anticoagulation therapy probably benefits those with advanced disease who are undergoing cancer treatments.
- Reviewing:
- Caruso V et al., Blood 2010 Jul 1; 115:5322.
- Related Searches: arterial thrombosis, central nervous system lymphoma, deep vein thrombosis, hodgkin's disease, lymphoma, lymphoma, non-hodgkin, pulmonary embolism, thrombosis, venous thrombosis
ASCO 2010 Report: Gastrointestinal Cancer Free
- July 13, 2010
- David H. Ilson, MD, PhD
- Oncology and Hematology
Genetic predictors of treatment outcomes; results from new drug trials
- Related Searches: avagast, bevacizumab, braf gene, cetuximab, chemotherapy, colorectal cancer, colorectal cancer metastatic, crystal, esophageal cancer, fluorouracil/leucovorin calcium/oxaliplatin, gastroesophageal cancer, gastrointestinal cancer, irinotecan, k-ras oncogene, mutation, opus, predictive marker, radiochemotherapy, secondary malignant neoplasm of pancreas
The Pathogenesis of Anemia in Patients with Hodgkin Lymphoma
- June 15, 2010
- David Green, MD, PhD
- Oncology and Hematology
Hepcidin and interleukin-6 play interrelated roles in the process.
- Reviewing:
- Hohaus S et al., J Clin Oncol 2010 May 20; 28:2538.
- Related Searches: anemia, hepcidin, hodgkin's disease, interleukin-6
Predicting Cure in Patients with Hodgkin Lymphoma
- March 10, 2010
- Michael E. Williams, MD
- Oncology and Hematology
The number of infiltrating tissue macrophages correlated strongly with treatment outcomes in classic Hodgkin lymphoma.
- Reviewing:
- Steidl C et al., N Engl J Med 2010 Mar 11; 362:875.
- Related Searches: biological markers, cancer survivorship, cd68 antigen, human, hodgkin's disease, macrophage, treatment failure
Gaining Insight into Cardiovascular Adverse Effects of Anthracyclines
- February 16, 2010
- William J. Gradishar, MD
- Oncology and Hematology
Substantial increases in aortic stiffness were observed 4 months after initiating anthracycline chemotherapy.
- Reviewing:
- Chaosuwannakit N et al., J Clin Oncol 2010 Jan 1; 28:166.
- Related Searches: adjuvant chemotherapy, anthracycline antibiotics, anthracycline toxicity, breast cancer, cardiac disease risk factor, leukemia, lymphoma
Report From the 51st American Society of Hematology Annual Meeting and Exposition: Malignant Hematology
- January 12, 2010
- Michael E. Williams, MD
- Oncology and Hematology
The latest reports on treatment of B-cell lymphomas and high- and low-risk Hodgkin lymphomas
- Related Searches: anthracycline antibiotics, b-cell lymphoma, beacopp protocol, bendamustine, bleomycin/dacarbazine/doxorubicin/vinblastine protocol, diffuse large b-cell lymphoma, doxorubicin, etoposide, follicular lymphoma, hodgkin's disease, lymphoma, mantle-cell, lymphoma, non-hodgkin, radiation therapy, r-chop regimen, rituximab
Familial Risk for Chronic Lymphocytic Leukemia
- June 9, 2009
- Michael E. Williams, MD
- Oncology and Hematology
First-degree relatives of patients with CLL had elevated risk for lymphoproliferative malignancies, predominantly CLL.
- Reviewing:
- Goldin LR et al., Haematologica 2009 May; 94:647.
- Related Searches: chronic lymphocytic leukemia, familial risk factor, lymphoproliferative disorders

Prev
1
2
Next

Sort by:

Relevance
Date

Items 1 to 20 of 36 results

Search

Sign-In

Forgot your password? Login via Athens
or your institution

New to Journal Watch?

Copyright © 2012. Massachusetts Medical Society. All rights reserved.

Follow Us